Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.9% in the fourth quarter, Holdings Channel reports. The firm owned 1,899 shares of the biopharmaceutical company’s stock after buying an additional 139 shares during the period. Motley Fool Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $447,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Jennison Associates LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $61,160,000. Strategic Financial Concepts LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $41,529,000. Truist Financial Corp raised its stake in Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after purchasing an additional 2,539 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after purchasing an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after purchasing an additional 2,285 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several research reports. Stifel Nicolaus raised their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research note on Monday. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Scotiabank increased their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a report on Monday. Chardan Capital reissued a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $316.25.

Insider Buying and Selling

In other news, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock valued at $19,958,097 in the last three months. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 1.8 %

Shares of ALNY stock opened at $262.16 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a 50 day moving average price of $259.89 and a 200 day moving average price of $260.57. The stock has a market capitalization of $34.10 billion, a P/E ratio of -120.81 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.